
Please try another search
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.
Name | Age | Since | Title |
---|---|---|---|
Shyam Sunder Bhartia | 69 | 1978 | Chairman |
Hari Shanker Bhartia | 67 | 1982 | Co-Chairman |
Arun Seth | 73 | 2018 | Independent Non-Executive Director |
Harsh Mahajan | 66 | 2024 | Independent Director |
Arjun Shanker Bhartia | 37 | 2017 | Joint MD & Director |
Priyavrat Bhartia | 48 | 2017 | MD & Director |
Arvind Chokhany | 52 | 2021 | Group CFO & Whole-Time Director |
Vivek Mehra | 67 | 2017 | Independent Non-Executive Director |
Sushil Kumar Roongta | 75 | 2017 | Independent Non-Executive Director |
Arul Ramakrishan | 59 | 2024 | Additional Director & Whole-time Director |
Shivpriya Nanda | 61 | 2024 | Independent Director |
Shirish Gundopant Belapure | 72 | 2023 | Additional Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review